Jozef Urdzik

Jozef Urdzik

Auto-generated profile, based on publicly available information

Jozef Urdzik

Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
CMChristopher Månsson
Christopher Månsson
RBRichard Brahmstaedt
Richard Brahmstaedt
PNPeter Nygren
Peter Nygren
ANAnders Nilsson
Anders Nilsson
JUJozef Urdzik
Jozef Urdzik
BKBritt-Marie Karlson
Britt-Marie Karlson
Background/Aim: Irreversible electroporation (IRE) has recently been used as an experimental ablation treatment following systemic chemotherapy in locally advanced pancreatic cancer (LAPC). The primary aim of this study was to evaluate survival of LAPC patients after IRE prior to chemotherapy. The secondary aim was to examine the complication rates. Patients and Methods: Twenty-four patients with LAPC were included and treated with percutaneous ultrasound-guided IRE under general anesthesia. Survival data from the National Quality Registry for Pancreatic and Periampullary Cancer for LAPC during the same period were used for comparison. Results: The median survival after diagnosis was 13.3 months in the IRE group compared to 9.9 months in the registry group (p=0.511). Six patients had a severe complication after IRE treatment. Conclusion: No obvious gain in survival was observed with IRE as the first line treatment of LAPC and IRE was associated with severe complications. This study does not support percutaneous IRE in this setting.

5 October 2021 in iScience
Verified
Journal Article
Open access
NHNiklas Handin
Niklas Handin
EMEvgeniya Mickols
Evgeniya Mickols
MÖMagnus Ölander
Magnus Ölander
JRJakob Rudfeldt
Jakob Rudfeldt
KBKristin Blom
Kristin Blom
PAPer Artursson
Per Artursson
Spheroid cultures of primary human hepatocytes (PHH) are used in studies of hepatic drug metabolism and toxicity. The cultures are maintained under different conditions, with possible confounding results. We performed an in-depth analysis of the influence of various culture conditions to find the optimal conditions for the maintenance of an in vivo like phenotype. The formation, protein expression, and function of PHH spheroids were followed for three weeks in a high-throughput 384-well format. Medium composition affected spheroid histology, global proteome profile, drug metabolism and drug-induced toxicity. No epithelial-mesenchymal transition was observed. Media with fasting glucose and insulin levels gave spheroids with phenotypes closest to normal PHH. The most expensive medium resulted in PHH features most divergent from that of native PHH. Our results provide a protocol for culture of healthy PHH with maintained function - a prerequisite for studies of hepatocyte homeostasis and more reproducible hepatocyte research.

7 September 2022 in HPB
Verified
Journal Article
Open access
PFPetter Frühling
Petter Frühling
CSCecilia Strömberg
Cecilia Strömberg
BIBengt Isaksson
Bengt Isaksson
JUJozef Urdzik
Jozef Urdzik
The optimal treatment strategy for patients with synchronous colorectal liver metastases (CRLM) is unclear. The aim of this study was to compare the outcome of the simultaneous, liver-first, and colorectal-first surgical approaches. All consecutive patients who had been resected with curative intent for CRLM were included. A Cox regression model was constructed, and an intention-to-treat analysis was performed between the liver-first and the simultaneous approaches, after propensity score matching. 658 patients were included in the analysis. 92 patients had a simultaneous resection, 163 patients had liver-first, and 403 patients had a colorectal-first approach. Overall survival was 54.9 months (95% CI 39.2-70.4) in the liver-first group, 54.5 months (95% CI 46.8-62.3) in colorectal-first group, and 59.6 months (95% CI 42.2-77.0) in the simultaneous group (log-rank p =0.850). In the matched cohort there were no differences in Clavien-Dindo 3a (p = 0.992) or 3b and greater (p = 0.999). Median overall survival was for liver-first group 42.2 months (95% CI 26.3-58.2), and for the simultaneous group 56.2 months (95% CI 47.1-65.4) (stratified log-rank p = 0.455). A simultaneous approach was not associated with worse overall survival or morbidity compared to a liver-first approach.